Safety, Tolerability, and Distribution of Laquinimod Eye Drops : The LION Study

Key facts

Sponsor

Quan Dong Nguyen

Intervention

Laquinimod eye drops(drug)

Enrollment

12 target

Eligibility

18 years · All sexes

Timeline

2024 – 2025

Study locations (1)

• Spencer Center for Vision Research at the Byers Eye Institute, Palo Alto, California, United States

Collaborators

Global Ophthalmic Research Center (GORC)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Uveitis

Additional recruiting or active studies for the same condition.

• RECRUITINGNCT06974162
  Metagenomics for Ocular Inflammation
  Moorfields Eye Hospital NHS Foundation Trust
• ACTIVE NOT RECRUITINGNCT06821971
  Study of Risk Factors for Therapeutic Failure in Chronic Non-Infectious Uveitis After First-Line Immunosuppressive Therapy
  Centre Hospitalier Universitaire, Amiens
• RECRUITINGEARLY PHASE1NCT07145008
  Suprachoroidal Triamcinolone in Macular Edema for Patients With Non-Infectious Uveitis Resistant to Subtenon Triamcinolon
  University of Baghdad
• ACTIVE NOT RECRUITINGNANCT06585670
  Mindfulness Approach for Reducing Anxiety and Gloom in Ocular Inflammatory Diseases
  University of California, San Francisco
• ACTIVE NOT RECRUITINGNCT06686641
  Incidence of Macular Edema in a Uveitis Population
  Aalborg University Hospital
• ACTIVE NOT RECRUITINGNANCT06310837
  Effect of Immunosuppressants With Adalimumab Biosimilars vs Corticosteroids on Noninfectious Uveitis
  Zhongshan Ophthalmic Center, Sun Yat-sen University
• RECRUITINGNCT05727540
  The Cohort Study of Uveitis Patients
  Zhongshan Ophthalmic Center, Sun Yat-sen University
• RECRUITINGNCT05592717
  A Study of YUTIQ® 0.18 mg Intravitreal Implant for the Management of Chronic Non-infectious Uveitis
  Tianjin Medical University

See all trials for Uveitis →